Abstract
BackgroundTo find potential serum biomarkers of microwave ablation (MWA) for treatment of human lung cancer by 1H nuclear magnetic resonance (NMR)-based metabolomics analysis.MethodsSerum specimens collected from 43 healthy individuals, 39 patients with advanced non-small cell lung cancer (NSCLC) and 38 NSCLC patients treated with MWA, were subjected to 1H NMR-based metabolomics analysis. Partial least squares discriminant analysis was used to analyze the data.ResultsCompared with healthy controls, NSCLC patients showed significantly elevated serum levels of lactate, alanine, glutamate, proline, glycoprotein, phenylalanine, tyrosine and tryptophan, and markedly decreased serum levels of glucose, taurine, glutamine, glycine, phosphocreatine and threonine (p < 0.05). MWA treatment reversed the metabolic profiles of NSCLC patients towards the control group.Conclusions1H NMR-based metabolomics analysis enhanced the current understanding of the mechanisms involved in NSCLC, and uncovered the therapeutic potential of MWA for treatment of NSCLC. The above disturbed serum metabolites were proposed to be the potential biomarkers that may help to predict NSCLC and to evaluate the efficacy of MWA in the treatment of NSCLC.
Highlights
To find potential serum biomarkers of microwave ablation (MWA) for treatment of human lung cancer by 1H nuclear magnetic resonance (NMR)-based metabolomics analysis
Therapeutic effect evaluation of MWA is very important for doctors to and timely adjust the treatment plan to maximize the efficacy of thermal ablation therapy
Patients and samples Between 20 February 2014 and 30 May 2016 patients who met the following criteria were retrospectively enrolled in the study: (1) pathologically verified peripheral non-small cell lung cancer (NSCLC), (2) stage IIIB or IV, (3) chemotherapy-naive, (4) an Eastern Cooperation Oncology Group (ECOG) performance status of 0 to 2, and (5) adequate pulmonary, cardiac, hepatic, renal and hematological functions to allow anticancer treatment
Summary
To find potential serum biomarkers of microwave ablation (MWA) for treatment of human lung cancer by 1H nuclear magnetic resonance (NMR)-based metabolomics analysis. Surgery is the most preferred and effective method for lung cancer patients. Minimally invasive thermal therapy including radiofrequency ablation (RFA) and microwave ablation (MWA) are widely used in lung cancer patients in clinic [3], which use heat generated by the biological effects of tumor cells directly to cause irreversible damage or coagulation necrosis in tumor tissues [4]. Therapeutic effect evaluation of MWA is very important for doctors to and timely adjust the treatment plan to maximize the efficacy of thermal ablation therapy. Efficacy evaluation of thermal ablation is currently based on the anatomical imaging, morphology or pathology examination. The major disadvantages of these traditional indicators include poor sensitivity and specificity, which cannot effectively estimate the curative effects and predict prognosis of NSCLC patients [6]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
